Similar articles

• Guselkumab for plaque psoriasis.

  [No authors listed] [No authors listed] Aust Prescr. 2019 Jun;42(3):105-106. doi: 10.18773/austprescr.2019.031. Epub 2019 Apr 24. Aust Prescr. 2019. PMID: 31363311 Free PMC article. Review. No abstract available.
• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.

  Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Reich K, et al. J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057361 Clinical Trial.
• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.

  Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Blauvelt A, et al. J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057360 Clinical Trial.
• First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.

  Zhuang Y, Calderon C, Marciniak SJ Jr, Bouman-Thio E, Szapary P, Yang TY, Schantz A, Davis HM, Zhou H, Xu Z. Zhuang Y, et al. Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310. doi: 10.1007/s00228-016-2110-5. Epub 2016 Aug 11. Eur J Clin Pharmacol. 2016. PMID: 27515978 Clinical Trial.
• A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.

  Nawas Z, Hatch M, Ramos E, Liu M, Tong Y, Peranteau A, Tyring S. Nawas Z, et al. Skin Therapy Lett. 2017 Mar;22(2):8-10. Skin Therapy Lett. 2017. PMID: 28329405 Review.